FcgRIIB-deficient mice generated in 129 background (FcgRIIB 129 2/2 ) if back-crossed into C57BL/6 background exhibit a hyper- 
T he hyperactive phenotype of FcgRIIB KO mice confirms the important role of this inhibiting receptor for IgG in the negative regulation of activating Fc receptors on myeloid effector cells and in a negative feedback mechanism in B cells, controlling Ab production. However, the lupus phenotype of FcgRIIB 2/2 mice generated by gene targeting in 129-derived ES cells (FcgRIIB 129 2/2 ) and back-crossed into C57BL/6 (B6)
background (1) is surprising because genetic studies revealed that lupus susceptibility is a multigenic phenotype (2) . Genetic and functional studies have revealed contradictory data, making the role of FcgRIIB in autoimmunity controversial. The Fcgr2b gene is located in a locus within the distal region of mouse chromosome (Chr) 1, which is orthologous with an SLEassociated locus on human Chr 1. All lupus-prone mouse strains share the lupus-associated Sle1 haplotype of that locus, but B6 mice do not. In B6 congenic mice, the Sle1 locus causes loss of tolerance leading to anti-nuclear Ab (ANA) production, mild splenomegaly, but no fatal glomerulonephritis. The following observations in autoimmune-prone mice and systemic lupus erythematosis (SLE) patients suggest that the association with lupus of the Sle1 locus and its human ortholog can be attributed, at least partially, to polymorphisms in the Fcgr2b gene. Autoimmuneprone strains share a promoter haplotype and/or polymorphisms in the third intron of the Fcgr2b gene, which are associated with reduced FcgRIIB expression in germinal center B cells and plasma cells (3, 4) . In humans, the frequency of homozygosity for a single amino acid polymorphism (232T) in FcgRIIB, resulting in "loss of function" (5) , is at least doubled in individuals with SLE compared with that in healthy controls in three Asian and one Caucasian cohort (reviewed in Ref. 6) .
Several other observations, however, argue against a role of FcgRIIB in lupus. In humans, the association between the 232T polymorphism and SLE could not be confirmed with an AfricanAmerican or Caucasian-American cohort (7) . A recent genomewide association study in women of European ancestry with SLE identified susceptibility variants in 15 different genes but not in the Fcgr2b gene (8) . Moreover, a strong SLE association in Caucasians of a "gain of function" mutation in FcgRIIB, resulting in increased promoter activity, has been reported (9) . In mice, within the Sle1 locus four subloci, Sle1a-d, have been identified. In congenic B6 mice the presence of Sle1b is sufficient for the loss of tolerance resulting in ANA production. Surprisingly, genetic fine mapping placed the Fcgr2b gene not in, but just between, the Sle1a and Sle1b subloci (10) . Moreover, a B6 strain congenic for the Fcgr2b allele derived from the NZW autoimmune-prone strain did not develop autoimmunity (11) .
Importantly, the lupus-associated Sle1b haplotype is also present in the non-autoimmune strain 129. In agreement with this, a B6 strain congenic for the 129-derived distal part of Chr 1, encompassing the Sle1b locus, named Sle16, develops an autoimmune phenotype (12) . As a consequence, it may be the presence of the Sle16 locus that determines the autoimmune phenotype of FcgRIIB 129 2 .Yaa offspring did develop fatal lupus. These observations indicate that FcgRIIB deficiency does not cause autoimmunity but amplifies spontaneous autoimmunity determined by autoimmune susceptibility loci, such as Sle16 or Yaa.
Materials and Methods

Generation of the conditional C57BL/6 FcgRIIB KO mouse model
For the generation of FcgRIIB 2/2 mice on C57BL/6 background (FcgRIIB B6 2/2 ), a targeting vector was constructed based on a 12-kb fragment derived from the BAC clone RPCI23-87B18 of the RPCI 23 Female (C57BL/6J) mouse BAC genomic library (BACPAC Resources Center, Children's Hospital Oakland Research Institute, Oakland, CA). By using conventional cloning techniques, a neomycin selection cassette, flanked by loxP sites, was inserted in intron 3, and a third loxP site was inserted in intron 5 (Supplemental Fig. 1A ). Gene targeting was performed in C57BL/6-derived ES cells (Bruce4, kindly provided by Dr. Colin Stewart [National Cancer Institute, Frederick, MD]). Clones in which homologous recombination occurred were identified by Southern blotting (Supplemental Fig. 1B ) and subsequently injected in albino C57BL/6 blastocysts. The obtained chimeras were crossed with albino C57BL/6 mice, and the F1 positive for the FcgRIIB-targeted allele was crossed with the EIIaCre deleter strain and the resulting F2 with C57BL/6. The EIIaCre negative F3 were intercrossed resulting in the following homozygous recombinant FcgRIIB strains: the FcgRIIBB6 fl/fl with the floxed FcgRIIB gene without neo selection marker gene, and the FcgRIIBB6 2/2 , the FcgRIIB null mutant, in which the exons 4 and 5, encoding the second extracellular ligand binding and transmembrane domains, are deleted (Supplemental Fig. 1A ). Cre-mediated recombination was analyzed with PCR and Southern blot (Supplemental Fig. 1C, 1D ). Primer sequences were as follows: P1, 59-CCTTCATCTTTCCTGCCAAG-39; P2, 59-AAC-ACCAGCTGAGGGGTCT-39; P3, 59-CACCACTGTGGAGAAGGATG-39; P6, 59-TCACACCAGCAACACCTCTC-39. fl/fl and C57BL/6 mice was similar, whereas no FcgRIIB expression was observed in FcgRIIB B6 2/2 mice (Supplemental Fig. 1E ). Similar results of FcgRIIB expression were obtained with B cells and myeloid cells isolated from peripheral blood, bone marrow, and peritoneal cavity (data not shown).
Mice
FcgRIIB 129
2/2 mice, generated on 129 background, were a gift of Dr. T. Takai (Department of Experimental Immunology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan) (13) and back-crossed in our facility into C57BL/6J (Charles River, Maastricht, The Netherlands) background for eight generations. FcgRIII 2/2 mice backcrossed into C57BL/6J background for 13 generations have been described previously (14) . The C57BL6.Yaa congenic strain was generated as described (15) . C57BL/6.Yaa FcgRIIBB6
.Yaa mice were generated by intercrossing F1 progeny from FcgRIIBB6 2/2 females and C57BL/6.Yaa males.
The EIIaCre deleter strain (n = 12 on C57BL/6J background), was a kind gift of Dr. Heiner Westphal (National Institute of Child Health and Human Development, Bethesda, MD). C57BL/6J control mice were purchased from Charles River. Mice were housed and all experiments were performed at the specified pathogen free animal facilities of the Leiden University Medical Center except for the aging experiment with cohorts of male mice of the C57BL/6.Yaa congenic strain and the FcgRIIBB6 .Yaa strain, which was performed at the animal facilities of the University of Geneva. All experiments were approved by the local ethical committee and performed in accordance with national guidelines and regulations. Six-to twelve-week-old mice were used for the experiments unless stated otherwise. Mice were routinely checked for their genotype by PCR and cytofluorimetry.
Simple sequence length polymorphism and single nucleotide polymorphism analysis
Genotyping of the mice was carried out using simple sequence length polymorphism (SSLP) markers (listed in Supplemental Table IA) , standard PCR, and either 4% MetaPhor agarose (CambrexBioscience Rockland, Rockland, ME) or 16% polyacrylamide gels stained with ethidium bromide. The positions and sequences were determined from the Ensembl (http://www.ensembl.org/index.html) and Mouse Genome Informatics (http://www.informatics.jax.org) databases. Single nucleotide polymorphisms (SNPs) in the FcgRIIB flanking regions reported to be different between the 129 and C57BL/6 mouse strains (Supplemental Table IA) were amplified by PCR. The PCR products were purified and their nucleotide sequence determined.
Immunization with TNP-KLH
At day 0, mice were immunized i.p. with 100 mg 2,4,6, trinitrophenyl hapten conjugated keyhole limpet hemocyanin (TNP-KLH) (Biosearch Technologies) in alum (Merck) and boosted on day 49 with 100 mg TNP-KLH without alum. Serial blood samples were collected via the retro-orbital plexus on days 21, 28, and 56 after the primary immunization. The Ab response was determined by ELISA. Plates were coated with TNP-KLH (20 mg/ml) in 0.1 M carbonate buffer, pH 9.5, overnight at 4˚C. After washing with PBS/0.1% BSA/0.05% Tween 20, plates were blocked with PBS/1% BSA for 1 h at room temperature in a humid chamber, and samples, diluted in PBS (1:16,000), were incubated overnight at 4˚C. Plates were washed five times with PBS/0.05% Tween 20 and incubated with rabbit anti-mouse IgG HRP (1:2000) or rabbit anti-mouse IgG1 HRP (1:1000) in PBS/1% BSA/ 0.01% Tween 20 for 2 h at room temperature. Plates were developed using ABTS (Sigma), and their OD was read at 405 nm. Samples were compared with a standard curve prepared from the pooled sera.
In vitro phagocytosis assay
Bone marrow-derived macrophages were cultured from mice in 15% L-cell conditioned medium (L929) for 8 d, pretreated overnight with 20 ng/ml recombinant IL-4 to increase FcgRIIB expression, and subsequently incubated at 37˚C for 1 h with TNP-conjugated sheep RBCs (SRBCs) opsonized with anti-TNP IgG1 Abs. The ingested SRBCs were counted using a light microscope.
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Passive cutaneous anaphylaxis
Mice were injected intradermally in the ear with 20 ml of varying concentrations (1-3 mg) IgG1 anti-TNP mAb and 2 h later given an i.v. injection of 500 mg human serum albumin (HSA)-TNP in 100 ml PBS with 1% Evans blue. After 30 min, extravasation was visualized by blue staining of the ear as described previously (14) .
Monitoring the development of spontaneous autoimmune disease
Mice were monitored up to the age of 12 mo, and mortality was recorded. Moribund animals were killed before the 12 mo deadline and were counted as deceased. Blood and urine was collected periodically, and serological analyses were performed by ELISA to determine the autoantibody levels. After sacrifice, the mice were weighed, and organs were removed. Spleens were weighed, and kidneys were fixed in Bouin's solution (Sigma) for 4 h, transferred to ethanol 70%, and finally embedded in paraffin, whereas splenocytes were analyzed by flow cytometry.
Serological analyses
Antinucleosome Abs. Serum levels of anti-nucleosome Abs were determined by ELISA. Plates were coated overnight with S2 fraction of oligonucleosomes isolated from L1210 cells. After blocking with PBS/5% FCS/0.05% Tween 20, the plates were incubated with serially diluted serum (1:100, 1:200, 1:400) for 2 h at room temperature. Bound Abs were detected using goat anti-mouse Ig-HRP. Plates were developed with ABTS, and the OD was read at 415 nm. Titers were determined by comparison with a sample with a known concentration of mouse anti-nucleosome mAbs. Anti-dsDNA, anti-ssDNA, anti-chromatin, and anti-histone ELISA. Levels of anti-dsDNA, anti-ssDNA, anti-chromatin, and anti-histone Abs were measured by ELISA as described previously (16) . Results were expressed as arbitrary units relative to a standard positive sample derived from an MRL/Mp.lpr/lpr mouse pool. Detection of Coombs Abs. A flow cytometric assay was used to detect Coombs Abs using biotinylated rat anti-mouse k chain mAb (H139.52.1.5), followed by PE-conjugated streptavidin, as described previously (17) . The results are expressed as mean fluorescence intensity (MFI), analyzed with a FACSCalibur (BD Biosciences, San Jose, CA).
Assessment of renal pathology
Histological sections. Four-micrometer-thick kidney sections were processed and assessed as described previously (18) . IgG and C3 deposition. Kidneys were embedded in OCT, snap-frozen in isopentane cooled with liquid nitrogen, and stored at 270˚C. Fivemicrometer-thick frozen sections were processed and incubated as described previously (18) . All Abs were used at a dilution of 1:200 (except anti-C3 at 1:100). For semiquantitative immunofluorescence, all sections were examined at 3600 original magnification with an Olympus AX/70 Provis microscope and 2MP slider camera (Diagnostic Instruments). The mean intensity of 20 glomeruli for each sample was recorded in arbitrary fluorescence units as 0/trace, 1+, 2+, 3+, 4+. Proteinuria. Albumin concentration was determined in urine samples of mice using a standard rocket immunoelectrophoresis assay. A series of diluted urine samples (1:2, 1:4, or 1:16) in PBS alongside control samples of purified mouse albumin were run for 5-6 h at 500 V/40 mA in a 1% agarose gel in the presence of polyclonal rabbit anti-mouse albumin in Gelman buffer. The gel was dried overnight, stained with Coomassie blue, and analyzed.
Flow cytometry
Single-cell suspensions of spleens were prepared by mechanical disruption and labeled using specific mAbs. For flow cytometry analysis, CD4-PE (clone RM4-5; BD Biosciences), CD8b. 
Induction of arthritis
Induction and clinical evaluation of collagen-induced arthritis (CIA) and K/ B3N serum-induced arthritis was performed as described (19) . In the CIA model, on days 35 and 60 after the primary immunization, serum was collected for the measurement of anti-collagen type II (CII) Ab titers by ELISA. Because of the robust nature of the K/B3N serum-induced arthritis model, the relative increase in arthritis severity in the FcgRIIB 2/2 mice became only apparent when a suboptimal amount of serum (7.5 ml/g body weight) was injected, which induced only mild arthritis in control mice.
Induction of experimental nephritis
Induction and clinical evaluation of accelerated nephrotoxic nephritis (NTN) in mice was performed as described previously (18) . Mice were assessed daily for the development of proteinuria and hematuria (Haema Combistix).
Monocytosis
PBMCs were stained with M1/70 anti-CD11b and AFS98 anti-CD115 mAb in the presence of saturating concentration of 2.4G2 anti-FcgRII/III mAb and analyzed with a FACSCalibur (Becton Dickinson, Mountain View, CA), as described previously (20) . Percentages of CD11b + CD115 + monocytes (distinguished from polymorphonuclear leukocytes by their lower granularity, as reflected in low side-light scatter) among PBMCs were determined.
Statistics
Parametric data were represented as mean 6 SEM. Multiple groups were compared by ANOVA and further evaluated using Bonferroni or unpaired Student t test. Nonparametric data were represented by median and multiple groups compared by using a Kruskal-Wallis test or Mann-Whitney U test. A p value of 0.05 was considered statistically significant. Cumulative mortality was processed by using Gehan-Breslow-Wilcoxon test.
Results
Establishing two independent FcgRIIB
2/2 C57BL/6 mouse strains, which differ in their Fcgr2b flanking regions mouse was generated by gene targeting in 129-derived ES cells (13) and back-crossed for eight generations into C57BL/6/J background in our laboratory. The FcgRIIB B6 2/2 strain was generated by gene targeting in B6-derived Bruce4 ES cells and back-crossed for three generations into C57BL6/J background (Supplemental Fig. 1 ). The 129 and B6 origin of the flanking regions was confirmed by SNP analysis (Supplemental Table IA However, the difference is not significant due to the strong variation in anti-CII titers in FcgRIIB 129 2/2 mice, which might be attributed to their mixed 129/B6 background (Supplemental Fig.  2 ). In the passive K/B3N serum-induced arthritis model, which depends exclusively on downstream Ab effector pathways, both FcgRIIB KO strains developed more severe disease compared with mice had high serum titers of autoantibodies specific for dsDNA and ssDNA, chromatin and histone, confirming the published phenotype, in the serum of FcgRIIB B6 2/2 mice hardly any of these autoantibodies were detectable ( Fig. 2A-D ). This lack of autoantibodies was neither caused by a delay in onset nor restricted to ANA. At the age of 12 mo, at which the mice were sacrificed, ANA Abs were still undetectable (data not shown), whereas anti-erythrocyte Abs present in FcgRIIB 129 2/2 mice were also absent in FcgRIIB B6 2/2 mice (Fig. 2E) . Moreover, FcgRIIB B6 2/2 mice did not show other signs of systemic autoimmunity, such as splenomegaly (Fig. 2F) or an increase in the proportion of activated T and B cells (Table II) The presence of ANA has been strongly associated with the development of immune-complex glomerulonephritis resulting in kidney damage. A first sign of kidney failure is proteinuria. At the age of 8 mo, despite the absence of autoantibodies, 30% of the FcgRIIB B6 2/2 mice showed a small but significant increase in the urinary albumin level (between 10 and 30 mg protein/g creatinine) compared with wild-type control mice (Fig. 3A) . However, more substantial urinary albumin levels between 50 and 175 mg protein/ g creatinine were detected in 22% of the FcgRIIB 129 2/2 mice.
Careful examination of kidney sections of 12-mo-old mice revealed that all genotypes developed kidney pathology ranging from very mild in wild-type B6 controls, to moderate in 
FcgRIIB B6
2/2 mice, to severe in FcgRIIB 129 2/2 mice (Fig. 3B,   3C ). The pathology score in arbitrary categories from 0 to 4 correlated with increased mortality. Twenty-two percent of the FcgRIIB 129 2/2 mice developed fatal disease between the ages of 8 and 12 mo, whereas neither the FcgRIIB B6 2/2 nor the wild-type control mice developed fatal disease even at the age of 12 mo (Fig.  3D) . These results show that the Sle16-driven nonlethal autoimmune features culminate in fatal lupus in the absence of functional FcgRIIB, suggesting epistatic interactions between the Sle16 locus and the Fcgr2b gene. Moreover, the significant increase of IgG and C3 depositions in the kidneys of 12-mo-old FcgRIIB B6 2/2 mice (Fig. 3B , Table III) in the absence of substantial autoantibody titers suggests that in the absence of FcgRIIB, the clearance of IgG-IC is impaired. This is in agreement with our previous observations in a model of Ag-induced arthritis (23) and might point to an important role of FcgRIIB on resident mesangial cells, on which FcgRIIB is the most abundantly expressed FcgR (24) , in the clearance of IgG-IC in the kidney.
Spontaneous autoimmunity in FcgRIII 129
2/2 mice with
129-derived Sle16 locus
To confirm further the contribution of the Sle16 locus to lowering the threshold for breaking tolerance in B6 mice, the development mice) and back-crossed 13 generations into B6 background. The presence of the 129-derived flanking Sle16 region was confirmed by SNP analysis (data not shown). FcgRIII 129 2/2 mice developed a high incidence of autoantibodies specific for dsDNA and ssDNA, nucleosome, chromatin, and histone ( Fig. 4A -E, Table  IV ) and showed other signs of systemic autoimmunity, such as splenomegaly (Fig. 4F ). In addition, in FcgRIII 129 2/2 mice the proportion of activated T and B cells was increased (Table V) , which is characteristic for the highly autoimmune FcgRIIB 129
mouse. These results demonstrate the strong contribution of the 129-derived Sle16 region in the development of spontaneous autoimmunity in B6 background (12) . However, increased mortality was not observed. The absence of FcgRIII, one of the activating FcgR expressed on circulating myeloid effector cells, which are indispensable for the development of glomerulonephritis (25), most likely increases resistance to lupus.
The 129-derived FcgRIIB flanking Sle16 region is a dominant lupus susceptibility locus
To investigate whether the 129-derived Sle16 locus is a recessive or dominant lupus susceptibility locus in B6 mice deficient for FcgRIIB, the development of lupus was analyzed in F1 offspring from the cross between FcgRIIB 129 2/2 and FcgRIIB B6 2/2 mice.
The F1 offspring (FcgRIIB 1293B6 2/2 ), containing one copy of the 129-derived flanking region (Sle16) and one copy of the B6-derived flanking region, developed splenomegaly and high ANA titers ( Fig. 5A-E) , although titers and incidence were decreased compared with titers and incidence in FcgRIIB 129 2/2 mice (Figs.
2A-D, 5A-D) suggesting a gene dose effect. This is in agreement with observations in Sle1 congenic strains. Kidney pathology was significantly increased in F1 mice compared with wild-type B6 mice (Fig. 5F, 5G ), whereas mortality was comparable between F1 and FcgRIIB 129 2/2 mice; 25 and 22%, respectively, died before the age of 1 y (Figs. 3D, 5H ). These results show that the 129-derived Sle16 locus is a dominant lupus susceptibility locus and explain the finding that heterozygosity of FcgRIIB 129 2/2 mice is sufficient for the development of rheumatoid factor (26) . In addition, it demonstrates that the lack of autoimmune disease in FcgRIIB B6 2/2 mice is not caused by the presence of an unidentified, dominant SLE-suppressor locus.
Positive epistasis between the FcgRIIB B6 2/2 allele and the Yaa locus in lupus FcgRIIB 129 2/2 male mice carrying the Yaa locus develop severe autoimmune disease characterized by striking splenomegaly, proteinuria with 90% penetrance, and a median survival of only 4 mo (21). This severe autoimmune phenotype has been explained by strong synergism between the Yaa locus and the Fcgr2b KO allele. However, synergism between the 129-derived flanking Sle16 region, with its NZW haplotype, and the B6 genome could not be excluded because strong synergism between Sle1 NZW and Yaa has been demonstrated (27) . To investigate the putative synergism between the Yaa and Fcgr2b KO allele in the absence of the 129-derived Sle16 locus, the FcgRIIB B6 2/2 strain was crossed with a Yaa B6 congenic strain, and the development of autoimmune disease in the FcgRIIB B6
2/2
.Yaa male offspring was analyzed. At the age of 10 mo, the male mice of the Yaa B6 congenic strain developed low but significantly increased anti-chromatin and antidsDNA autoantibody titers compared with those of males of the B6 control and FcgRIIB B6 2/2 strain (Fig. 6A, 6B ). The penetrance and the titers were further increased in the FcgRIIB B6 2/2 .Yaa male mice (Fig. 6A, 6B ), indicating that the absence of FcgRIIB enhanced the mild autoimmune phenotype of the C57BL/6.Yaa males. The FcgRIIB B6
.Yaa males displayed a moderate lupus phenotype with age characterized by splenomegaly, monocytosis, and substantial kidney pathology, but only 30% died between the ages of 10 and 12 mo (Fig. 6C-F and C57BL/6 female mice. G, Histological score of kidney pathology in PAS-stained kidney sections (as described in the legend of Fig. 3 Taken together, our results show that FcgRIIB is an autoimmune disease modifier and not, as has been postulated, a "single overriding factor," which may ultimately dictate whether the disease progresses or not (31) . Defining accurately the relative contribution of an individual disease modifier, such as FcgRIIB, to the development of a complex autoimmune disease is very difficult. The model of "threshold liability" can explain a substantial part of the highly severe phenotype of FcgRIIB 129 2/2 .Yaa male mice.
The penetrance of the autoimmune phenotype increases in relation to the increasing number of the susceptibility genes, Yaa, Sle16, and Fcgr2b 2/2 , present in the genome of these male mice.
However, in addition to the inheritance in a simplistic additive fashion, epistatic interactions might modify the inheritance of the autoimmune phenotype in a complex fashion that may not be additive (2) . This is demonstrated by our observations that in B6 mice, besides the reported positive epistatic interactions between the Sle1b and Yaa loci (27) , also epistatic interactions between Fcgr2b and yaa resulted in the development of lethal lupus. According to this "multiplicative model," the interactions of all susceptibility and suppressor alleles present in its genome determine the susceptibility of an individual. As a consequence, the contribution of an individual gene to the development of autoimmune disease can vary depending on all other susceptibility and suppressor loci present in the genome. In addition, environmental conditions also play an important role, as illustrated by the significant differences in kidney pathology between the two genetically 
